How Is Mesothelioma Diagnosed?

Step 1: Initial Evaluation and Imaging

The diagnostic process typically begins when a patient visits their doctor with persistent symptoms such as chest pain, shortness of breath, or abdominal swelling. The physician will take a detailed medical history — including any history of asbestos exposure — and order imaging tests to visualize the affected area.

Chest X-ray is usually the first imaging test ordered. It can reveal pleural effusion (fluid around the lungs), pleural thickening, or masses in the chest cavity. While an X-ray cannot confirm mesothelioma, it often provides the first indication that something abnormal is present.

CT scan (computed tomography) provides much more detailed cross-sectional images than an X-ray. According to the National Cancer Institute, CT scans can show the extent and location of tumors, pleural thickening, fluid accumulation, and involvement of nearby structures. CT scans are the primary imaging tool used in mesothelioma evaluation.

PET scan (positron emission tomography) uses a radioactive glucose tracer to identify metabolically active cancer cells. PET scans are particularly useful for determining whether mesothelioma has spread to lymph nodes or distant organs, which is critical for staging and treatment planning.

MRI (magnetic resonance imaging) may be used in some cases to provide additional detail about the tumor's relationship to the diaphragm, chest wall, or spine. MRI is especially helpful for surgical planning.

Step 2: Biopsy — The Definitive Test

Imaging tests can strongly suggest mesothelioma, but a tissue biopsy is required for a definitive diagnosis. The biopsy provides cells that pathologists can examine under a microscope to confirm the presence of malignant mesothelioma. Several biopsy methods are used.

Thoracoscopy (VATS). For suspected pleural mesothelioma, video-assisted thoracoscopic surgery is the most common and reliable biopsy method. A small camera and surgical instruments are inserted through small incisions in the chest wall, allowing the surgeon to directly visualize the pleura and obtain tissue samples. This procedure provides the largest and most accurate tissue samples.

Laparoscopy. For suspected peritoneal mesothelioma, laparoscopy serves the same function in the abdomen. A camera is inserted through a small abdominal incision to visualize the peritoneum and collect tissue samples.

Needle biopsy (core needle or fine needle aspiration). In some cases, a needle is guided by CT scan or ultrasound to extract tissue or fluid from a suspicious area. While less invasive than surgical biopsy, needle biopsies may not always provide enough tissue for a definitive diagnosis, particularly when differentiating mesothelioma from other cancers.

Fluid analysis (cytology). Fluid drained from a pleural effusion or ascites can be tested for cancer cells. However, fluid cytology alone is often insufficient for a confirmed mesothelioma diagnosis because the cells can be difficult to distinguish from other types of cancer or reactive mesothelial cells. Most oncologists require a tissue biopsy for confirmation.

Step 3: Pathology and Immunohistochemistry

Once biopsy tissue is obtained, pathologists perform a detailed analysis to confirm the diagnosis and determine the cell type. This is one of the most critical steps in the diagnostic process.

Immunohistochemistry (IHC) is the primary technique used to diagnose mesothelioma. Pathologists apply a panel of antibody-based stains to the tissue sample. Mesothelioma cells typically test positive for certain markers (calretinin, WT-1, CK5/6, D2-40) and negative for others (CEA, TTF-1, BerEP4). The American Cancer Society notes that this panel approach is essential because no single marker is definitive for mesothelioma.

The pathology report will also identify the cell type — epithelioid, sarcomatoid, or biphasic — which significantly affects prognosis and treatment options. Epithelioid mesothelioma responds best to treatment, while sarcomatoid has the poorest prognosis.

Step 4: Staging

After mesothelioma is confirmed, staging determines how far the cancer has spread. Staging is essential for treatment planning and prognosis estimation. Pleural mesothelioma uses the TNM staging system:

• T (Tumor): How large is the primary tumor and how far has it grown into nearby structures?
• N (Nodes): Has the cancer spread to nearby lymph nodes?
• M (Metastasis): Has the cancer spread to distant organs?

These factors combine to determine an overall stage from I to IV. Stage I indicates localized disease with the best treatment options, while stage IV indicates distant spread. Additional imaging tests — including PET scans and sometimes mediastinoscopy (examination of lymph nodes in the chest) — may be performed during staging.

Peritoneal mesothelioma does not have a universally accepted staging system. Instead, surgeons often assess the extent of disease using the Peritoneal Cancer Index (PCI), which scores the amount of tumor throughout the abdominal cavity to determine whether surgery is feasible.

Blood Markers and Emerging Diagnostic Tools

Researchers are developing blood-based tests that may help with earlier mesothelioma detection in the future.

Mesothelin (SMRP): Soluble mesothelin-related peptides are elevated in the blood of many mesothelioma patients. The MESOMARK blood test measures SMRP levels and can be useful for monitoring treatment response, though it is not specific enough for standalone diagnosis.

Fibulin-3: This protein has shown promise as a blood biomarker for mesothelioma in research studies. Elevated fibulin-3 levels have been detected in mesothelioma patients, though the test is not yet part of standard clinical practice.

Osteopontin: Another blood marker under investigation, osteopontin levels tend to be elevated in mesothelioma patients. Like other blood markers, it is not yet reliable enough for definitive diagnosis but may complement other diagnostic methods.

Currently, no blood test alone can diagnose mesothelioma. These markers are most useful as part of a broader diagnostic evaluation or for monitoring known disease.

Differential Diagnosis and Second Opinions

Mesothelioma can be difficult to distinguish from other conditions, particularly lung adenocarcinoma (a common form of lung cancer) and reactive mesothelial hyperplasia (a benign condition). Misdiagnosis is not uncommon, especially when tissue samples are small or when pathologists have limited experience with mesothelioma.

For this reason, seeking a second opinion from a pathologist experienced in mesothelioma is strongly recommended, particularly if the initial diagnosis is uncertain. Many patients have their biopsy slides reviewed at major cancer centers where pathologists regularly evaluate mesothelioma cases.

The time from initial symptoms to confirmed diagnosis varies but typically ranges from several weeks to several months. Delays can occur when symptoms are initially attributed to more common conditions like pneumonia or irritable bowel syndrome. Disclosing any history of asbestos exposure to your physician can help accelerate the diagnostic process.